negative mouse cd8 tcell Search Results


mouse cd8 tcell purification kit miltenyi biotech  (Miltenyi Biotec)
97
Miltenyi Biotec mouse cd8 tcell purification kit miltenyi biotech
Mouse Cd8 Tcell Purification Kit Miltenyi Biotech, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/gentleMACS+Octo+Dissociator+with+Heaters/pm32330455-256-106-111
Average 97 stars, based on 1 article reviews
mouse cd8 tcell purification kit miltenyi biotech - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
easysep mouse naive cd8 tcell isolation kits  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc easysep mouse naive cd8 tcell isolation kits
Easysep Mouse Naive Cd8 Tcell Isolation Kits, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/easysep+human+t+cell+isolation+kit/pm32998985-84-19-29
Average 90 stars, based on 1 article reviews
easysep mouse naive cd8 tcell isolation kits - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
themagcellect human cd8þ tcell isolation kit  (R&D Systems)
94
R&D Systems themagcellect human cd8þ tcell isolation kit
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Themagcellect Human Cd8þ Tcell Isolation Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/MagCellect+Human+CD8%2B+T+Cell+Isolation+Kit/10__1158_slash_0008___5472__can___21___2362-97-11-17
Average 94 stars, based on 1 article reviews
themagcellect human cd8þ tcell isolation kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
negative mouse cd8 tcell  (Miltenyi Biotec)
97
Miltenyi Biotec negative mouse cd8 tcell
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Negative Mouse Cd8 Tcell, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/CD8a%2B+T+Cell+Isolation+Kit%2C+mouse/pm32330455-400-8-12
Average 97 stars, based on 1 article reviews
negative mouse cd8 tcell - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
anti-mouse cd8 magnetic particles dm  (Becton Dickinson)
90
Becton Dickinson anti-mouse cd8 magnetic particles dm
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Anti Mouse Cd8 Magnetic Particles Dm, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/anti+mouse+cd4+magnetic+particles/10__1158_slash_2159___8290__cd___20___0603-282-8-13
Average 90 stars, based on 1 article reviews
anti-mouse cd8 magnetic particles dm - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cd4 antibody  (NSJ Bioreagents)
99
NSJ Bioreagents cd4 antibody
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Cd4 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/CD4+Antibody/custom%40v8352%4010%2E1089%2Fthy%2E1991%2E1%2Ei
Average 99 stars, based on 1 article reviews
cd4 antibody - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
anti cd8 mab  (Bio X Cell)
97
Bio X Cell anti cd8 mab
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Anti Cd8 Mab, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/Anti-CD8+Cd8A+Antibody/pm41253055-57-6-9
Average 97 stars, based on 1 article reviews
anti cd8 mab - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
msigdb c2  (Broad Institute Inc)
90
Broad Institute Inc msigdb c2
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Msigdb C2, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/msigdb+c2/pmc04867636__srep26061___s1-13452-20-2
Average 90 stars, based on 1 article reviews
msigdb c2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
magnetic beads  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc magnetic beads
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Magnetic Beads, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/magnetic+beads/pm35917405-286-18-22
Average 90 stars, based on 1 article reviews
magnetic beads - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
imag cell separation magnet  (Becton Dickinson)
90
Becton Dickinson imag cell separation magnet
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Imag Cell Separation Magnet, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/imag+cell+separation+magnet/10__1158_slash_2159___8290__cd___20___0603-282-18-22
Average 90 stars, based on 1 article reviews
imag cell separation magnet - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
rat-anti-pig -apc  (Becton Dickinson)
90
Becton Dickinson rat-anti-pig -apc
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Rat Anti Pig Apc, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/rat+anti+pig++apc/pm31923451-103-39-43
Average 90 stars, based on 1 article reviews
rat-anti-pig -apc - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
mouse monoclonal antibodies conjugated with fluorescein isothiocyanate and phycoerythrin cd3/cd4  (Becton Dickinson)
90
Becton Dickinson mouse monoclonal antibodies conjugated with fluorescein isothiocyanate and phycoerythrin cd3/cd4
Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of <t>CD8þ</t> T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.
Mouse Monoclonal Antibodies Conjugated With Fluorescein Isothiocyanate And Phycoerythrin Cd3/Cd4, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/negative+mouse+cd8+tcell/fluorescein+isothiocyanate+or+phycoerythrin+conjugated+monoclonal+anti+mouse+antibodies/pm10232438-94-16-23
Average 90 stars, based on 1 article reviews
mouse monoclonal antibodies conjugated with fluorescein isothiocyanate and phycoerythrin cd3/cd4 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.

Journal: Cancer Research

Article Title: FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance

doi: 10.1158/0008-5472.can-21-2362

Figure Lengend Snippet: Figure 1. Erdafitinib and infigratinib inhibit bladder tumor growth and induce T-cell suppression accompanied with PD-L1 upregulation in mice. A and B, The overview of experimental plan in Luciþ MB49 tumor-bearing C57BL/6 (A) and nude (B) mice model. C and D, Bioluminescence images of Luciþ MB49 tumor-bearing mice model in different groups. E and F, Quantification of bioluminescence intensity (mean SD, n ¼ 5). G and H, Macroscopic images of excised bladder tumors. Scale bars, 1 cm. I and J, Tumor weight after erdafitinib and infigratinib treatment (mean SD, n ¼ 5). K and L, Ultrasound images of orthotopic bladder tumors (red dash lines), hematoxylin and eosin (H&E)–stained sections of tumors, and immunofluorescence images of the indicated markers for Ki67 (red), cytokine 7 (green), and DAPI (blue) in C57BL/6 and nude mice. Scale bars in ultrasound images, 2 mm, 500 mm for hematoxylin and eosin staining, and 20 mm for immunofluorescence images. M, PD-L1 t-SNE plots of gated flow cytometrydata generated bycells in tumor tissue from erdafitinib and infigratinib treatment. Numbers on the right edge represent the proportion of PD-L1 positive cells. N, Plot showing the proportion of PD-L1 positive cells (mean SD, n ¼ 3). O, Intratumoral CD3þCD8þ T-cell proportions were analyzed by flow cytometry. P, Plot showing the proportion of tumor-infiltrating CD3þCD8þ T cells in tumor-bearing mice with different treatment (mean SD, n ¼ 3). Q, Flow cytometry analysis showing the granzyme B–positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). R, Statistical diagram showing the granzyme B–positive ratio in CD8þ T cells (left) and granzyme Bþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). S, Flow cytometry analysis showing the TNFa-positive ratio of CD8þ T cells in tumor (mean SD, n ¼ 3). T, Statistical diagram showing the TNFa-positive ratio of CD3þCD8þ T cells (left) and TNFaþ CD8þ T cells (right) in tumor (mean SD, n ¼ 3). , P < 0.01; , P < 0.001; , P < 0.0001; one-way ANOVA.

Article Snippet: Enrichment of CD8þT cells was performed bymagnetic cell sorting (MACS) using theMagCellect Human CD8þ TCell Isolation Kit (R&D Systems) and MagCellect Mouse CD8þ T Cell Isolation Kit (R&D Systems) following the manufacturer’s instructions.

Techniques: Staining, Generated, Cytometry, Flow Cytometry